Profile of ALLAKOS INC(NASDAQ:ALLK) stock

ALLAKOS INC7.21

NASDAQ:ALLK (2/3/2023, 7:24:30 PM)-0.36 (-4.76%)

After market: 7.2 -0.01 (-0.14%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-07 2022-11-07/amc	Earnings (Next)	02-27 2023-02-27/amc
Ins Owners	3.47%	Inst Owners	76.85%
Market Cap	614.32M	Shares	85.20M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	54.12
IPO	07-19 2018-07-19

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Company Info

ALLAKOS INC

825 Industrial Road, Suite 500

San Carlos CALIFORNIA 94065

P: 16505975002.0

CEO: Robert Alexander

Employees: 192

Website: http://www.allakos.com/

ALLK News

2 months ago - Allakos Inc.Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies...

2 months ago - Allakos Inc.Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

3 months ago - Allakos Inc.Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known...